Comparing the current results to its competitors, Hookipa Pharma Inc reported Revenue decrease in the 1 quarter 2025 year on year by -94.52 %, despite the revenue increase by the most of its competitors of 3.86 %, recorded in the same quarter.
Hookipa Pharma Inc 's Comment on Competition and Industry Peers
The competitive landscape comprises large and specialty pharmaceutical, biopharmaceutical, and biotechnology companies, as well as academic research institutions, governmental agencies, and public and private research organizations. Competitors utilize various technologies focused on therapeutic areas such as adoptive cell therapies and active immunization. Many small biotechnology companies collaborate with larger firms to support research, development, commercialization, or to combine treatment approaches. The company expects competition to increase with the emergence of new therapies, technologies, and data in immunotherapy and the treatment of infectious diseases and cancers. Competition also includes current standard of care treatments and numerous commercial and academic preclinical studies and clinical trials.
May 23, 2024
CSIMarket.com - May 23, 2024HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a biopharmaceutical company focused on developing immunotherapeutics based on its innovative arenavirus platform, recently released updated positive results from its Phase 1/2 clinical trial of HB-200. The trial investigated the potential of HB-200 in treating human papillomavirus 16 positive (HPV16+) head and neck cancers. The announced data, published in the company s abstract for the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting, provides crucial support for the design of the upcoming pivotal Phase 2/3 trial for HB-200 in combination with pembrolizumab as a first-line treatment.The published data from the Phase ...
ImmIx Biopharma Inc is a biotechnology company that focuses on developing novel therapeutics for the treatment of cancer. Their business model involves conducting extensive research and development to discover and optimize drug candidates, followed by preclinical and clinical testing to assess their safety and effectiveness. They aim to collaborate with pharmaceutical companies or seek licensing agreements to further develop and commercialize their biopharmaceutical products.
Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.
The business model of Innovation1 Biotech Inc involves developing and commercializing innovative biotechnological products and solutions for various industries. The company focuses on research, development, and manufacturing, aiming to provide cutting-edge biotech solutions that meet the needs of diverse markets.
Nkarta Inc is a biotechnology company with a business model centered on developing and commercializing engineered natural killer (NK) cell therapies for cancer patients. By utilizing proprietary technologies and expertise in genetic engineering, the company aims to enhance the therapeutic potential of NK cells and address unmet needs in the field of oncology. Nkarta Inc focuses on research, development, and production of these advanced cell therapies, collaborating with partners and regulators to bring innovative treatments to patients.
Sources:
Hookipa Pharma inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Hookipa Pharma inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
